

F3
d) a 293 embryonic kidney cell; and
e) a Cos kidney fibroblast cell; and
allowing said cell culture to live under
conditions wherein said nucleic acid molecule is expressed in
said cell culture.

FN
47. (Amended) The host cell of claim 46, wherein said
mammalian cell is a human cell.

REMARKS

Applicants request reconsideration of the above-identified application in view of the foregoing amendments and the following remarks. Applicants acknowledge with appreciation the courtesy extended to their representatives during telephone interviews of May 7 and 15, 2003 during which proposed claim amendments were discussed. Applicants make those interviews of record herein.


In order to expedite allowance of this application, applicants have amended claims 1, 10, 28 and 47 as indicated herein. The amendments are believed to be consistent with subject matter deemed allowable by the Examiner at this time. As a result, the claims pending in this application will be 1-4, 6-8, 10, 28, 30-31 and 39-47.

Applicants have amended claim 28 to further define the "soluble fragment" by incorporating the functional binding characteristics also recited in claim 4. Support for this amendment may be found, for example, at page 16, lines 3-16; and pages 36-37. Applicants have also amended claims 1 and 10 to replace the term "purified" with the term "pure" to provide consistency in the claim language. Finally, applicants have amended claim 47 to replace the term "mammalian" with the term "host" to parallel its antecedent basis.

None of the claim amendments constitutes new matter.

Applicants request that the Examiner consider the requested amendments and remarks and pass this application to issue.

Respectfully submitted,


James F. Haley, Jr.
(Reg. No. 27,794)
Margaret A. Pierri
(Reg. No. 30,709)
Attorneys for Applicants
Connie Wong
(Limited Recognition)
Agent for Applicants
FISH & NEAVE
Customer No. 1473

1251 Avenue of the Americas
New York, New York 10020-1105
Tel.: (212) 596-9000
Fax: (212) 596-9090

Appendix of Amendments

1. (Five Times Amended) A substantially [purified] pure nucleic acid comprising consecutive nucleotides that encode a human TRELL polypeptide, wherein said TRELL polypeptide comprises the amino acid sequence of SEQ ID NO:4.

10. (Three Times Amended) A method for producing substantially pure TRELL comprising the steps of culturing the host cell of claim 8 and isolating TRELL from said transformed host cell to obtain substantially [purified] pure TRELL.

28. (Four Times Amended) A method of expressing a TRELL polypeptide in an animal cell culture comprising:

introducing a vector comprising a nucleic acid molecule having consecutive nucleotides that encode said TRELL polypeptide into said cell culture, wherein said TRELL polypeptide comprises the amino acid sequence of SEQ ID NO:4, or a soluble fragment thereof that is capable of binding to a cell selected from the group consisting of:

- a) a K562 promyelocytic cell;
- b) a THP-1 monocytic leukemia cell;
- c) an HT29 colon adenocarcinoma cell;
- d) a 293 embryonic kidney cell; and
- e) a Cos kidney fibroblast cell; and

allowing said cell culture to live under conditions wherein said nucleic acid molecule is expressed in said cell culture.

47. (Amended) The [mammalian] host cell of claim 46,
wherein said mammalian cell is a human cell.